John L. Lamattina - Nov 27, 2024 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Director
Signature
By: Andrew Reardon, Attorney-in-Fact For: For: John L. LaMattina
Stock symbol
LGND
Transactions as of
Nov 27, 2024
Transactions value $
-$171,668
Form type
4
Date filed
12/2/2024, 08:05 PM
Previous filing
Jun 18, 2024

Transactions Table

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Non-Qualified Stock Option (right to buy) Options Exercise $0 -2.41K -100% $0.00 0 Nov 27, 2024 Common Stock 2.41K $52.30 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Option was previously reported as a Grant of 2,754 shares on April 24, 2015, which vested in full on April 24, 2016, at an exercise price of $89.7500 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.